Utilisation of co-testing (human papillomavirus DNA testing and cervical cytology) after treatment of CIN: a survey of GPs’ awareness and knowledge

Background - Patients have an increased risk of persistent/recurrent cervical disease if they received treatment for a high-grade squamous intraepithelial lesion (HSIL). Consequently, understanding whether co-testing (human papillomavirus [HPV] DNA testing and cervical cytology) is fully utilised by...

Full description

Bibliographic Details
Main Authors: Munro, A., Codde, J., Semmens, James, Leung, Y., Spilsbury, Katrina, Williams, Vincent, Steel, N., Cohen, P., Pavicic, H., Westoby, V., O'Leary, Peter
Format: Journal Article
Published: The Royal Australian College of General Practitioners 2015
Subjects:
Online Access:http://www.racgp.org.au/download/Documents/AFP/2015/January/February/research-munro.pdf
http://hdl.handle.net/20.500.11937/10779
_version_ 1848747626608984064
author Munro, A.
Codde, J.
Semmens, James
Leung, Y.
Spilsbury, Katrina
Williams, Vincent
Steel, N.
Cohen, P.
Pavicic, H.
Westoby, V.
O'Leary, Peter
author_facet Munro, A.
Codde, J.
Semmens, James
Leung, Y.
Spilsbury, Katrina
Williams, Vincent
Steel, N.
Cohen, P.
Pavicic, H.
Westoby, V.
O'Leary, Peter
author_sort Munro, A.
building Curtin Institutional Repository
collection Online Access
description Background - Patients have an increased risk of persistent/recurrent cervical disease if they received treatment for a high-grade squamous intraepithelial lesion (HSIL). Consequently, understanding whether co-testing (human papillomavirus [HPV] DNA testing and cervical cytology) is fully utilised by general practitioners (GPs) is paramount. Methods - After consultation with key stakeholders, an anonymous, self-completion questionnaire was developed and disseminated to GPs who had provided cervical cytology. Results - Responses were received from 745 GPs (30.9% response rate). A significant number (34.3%) of GPs were unaware of the use of co-testing (HPV DNA testing and cervical cytology) for the management of patients after HSIL treatment. Additionally, the majority of GPs reported they did not ‘always’ receive a clear follow-up plan for patients after treatment of an HSIL. Discussion - GPs require further support and education to ensure successful adoption of co-testing (HPV DNA testing and cervical cytology), specifically, for patients treated for an HSIL.
first_indexed 2025-11-14T06:52:08Z
format Journal Article
id curtin-20.500.11937-10779
institution Curtin University Malaysia
institution_category Local University
last_indexed 2025-11-14T06:52:08Z
publishDate 2015
publisher The Royal Australian College of General Practitioners
recordtype eprints
repository_type Digital Repository
spelling curtin-20.500.11937-107792017-01-30T11:20:57Z Utilisation of co-testing (human papillomavirus DNA testing and cervical cytology) after treatment of CIN: a survey of GPs’ awareness and knowledge Munro, A. Codde, J. Semmens, James Leung, Y. Spilsbury, Katrina Williams, Vincent Steel, N. Cohen, P. Pavicic, H. Westoby, V. O'Leary, Peter human papillomavirus [HPV] DNA cytology cervical disease high-grade squamous intraepithelial lesion (HSIL) Background - Patients have an increased risk of persistent/recurrent cervical disease if they received treatment for a high-grade squamous intraepithelial lesion (HSIL). Consequently, understanding whether co-testing (human papillomavirus [HPV] DNA testing and cervical cytology) is fully utilised by general practitioners (GPs) is paramount. Methods - After consultation with key stakeholders, an anonymous, self-completion questionnaire was developed and disseminated to GPs who had provided cervical cytology. Results - Responses were received from 745 GPs (30.9% response rate). A significant number (34.3%) of GPs were unaware of the use of co-testing (HPV DNA testing and cervical cytology) for the management of patients after HSIL treatment. Additionally, the majority of GPs reported they did not ‘always’ receive a clear follow-up plan for patients after treatment of an HSIL. Discussion - GPs require further support and education to ensure successful adoption of co-testing (HPV DNA testing and cervical cytology), specifically, for patients treated for an HSIL. 2015 Journal Article http://hdl.handle.net/20.500.11937/10779 http://www.racgp.org.au/download/Documents/AFP/2015/January/February/research-munro.pdf The Royal Australian College of General Practitioners restricted
spellingShingle human papillomavirus [HPV] DNA
cytology
cervical disease
high-grade squamous intraepithelial lesion (HSIL)
Munro, A.
Codde, J.
Semmens, James
Leung, Y.
Spilsbury, Katrina
Williams, Vincent
Steel, N.
Cohen, P.
Pavicic, H.
Westoby, V.
O'Leary, Peter
Utilisation of co-testing (human papillomavirus DNA testing and cervical cytology) after treatment of CIN: a survey of GPs’ awareness and knowledge
title Utilisation of co-testing (human papillomavirus DNA testing and cervical cytology) after treatment of CIN: a survey of GPs’ awareness and knowledge
title_full Utilisation of co-testing (human papillomavirus DNA testing and cervical cytology) after treatment of CIN: a survey of GPs’ awareness and knowledge
title_fullStr Utilisation of co-testing (human papillomavirus DNA testing and cervical cytology) after treatment of CIN: a survey of GPs’ awareness and knowledge
title_full_unstemmed Utilisation of co-testing (human papillomavirus DNA testing and cervical cytology) after treatment of CIN: a survey of GPs’ awareness and knowledge
title_short Utilisation of co-testing (human papillomavirus DNA testing and cervical cytology) after treatment of CIN: a survey of GPs’ awareness and knowledge
title_sort utilisation of co-testing (human papillomavirus dna testing and cervical cytology) after treatment of cin: a survey of gps’ awareness and knowledge
topic human papillomavirus [HPV] DNA
cytology
cervical disease
high-grade squamous intraepithelial lesion (HSIL)
url http://www.racgp.org.au/download/Documents/AFP/2015/January/February/research-munro.pdf
http://hdl.handle.net/20.500.11937/10779